15319 52-week evaluation of the efficacy of dupilumab for moderate to severe atopic dermatitis in clinical practice: A Canadian multicenter retrospective study

Abstract

Our knowledge of dupilumab’s long-term efficacy for treatment of moderate to severe atopic dermatitis is limited to one phase III clinical trial evaluating dupilumab’s efficacy beyond 16 weeks. To assess dupilumab’s long-term efficacy, a retrospective chart review was conducted of patients meeting inclusion criteria (IGA ≥3, ≥18 years of age, ≥52 weeks of dupilumab treatment or discontinued dupilumab between weeks 16-52 due to lack of efficacy or due to an AE) at two tertiary hospitals in Toronto, Canada. Primary efficacy end point was measured by the proportion of patients reaching IGA 0/1 at week 52. 28/52 patients (54%) met IGA 0/1 at week 52. Further analysis revealed that 19/30 (63%) of the patients who initially met IGA 0/1 at week 16 maintained IGA 0/1 at week 52, while 5/18 (28%) of the non-responders at week 16 met IGA 0/1 at week 52. Of the four patients excluded from this analysis due to missing efficacy information at week 16, all achieved IGA 0/1 at week 52. In alignment with the results from the CHRONOS study, our study showed efficacy was maintained in the long-term with 54% of patients achieving IGA 0/1 at week 52. While majority of patients who initially met IGA 0/1 maintained efficacy at week 52 (63%), a considerable proportion of initial non-responders reached IGA 0/1 at week 52 (28%). Although larger studies are required, there may be value in continuing therapy despite lack of success in the short-term. This is especially important with limited safe and effective long-term treatments available.